FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Highlighting the potential of retatrutide as a novel therapeutic option for obesity management, focusing on its mechanism of action and clinical trial outcomes.
연구 도서관으로 돌아가기
retatrutideglucagon receptor agonistGIP receptor agonistGLP-1 receptor agonist

Highlighting the potential of retatrutide as a novel therapeutic option for obesity management, focusing on its mechanism of action and clinical trial outcomes.

May 16, 2026
Share

원본 논문

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Misra Saurav et al.Journal of basic and clinical physiology and pharmacology2025
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

Retatrutide: A Promising New Tool in the Fight Against Obesity

Published: May 16, 2026 | Source: Journal of basic and clinical physiology and pharmacology (2025) | Category: retatrutide, glucagon receptor agonist, GIP receptor agonist, GLP-1 receptor agonist

Overview

A recent systematic review published in the Journal of Basic and Clinical Physiology and Pharmacology highlights the potential of retatrutide as a novel therapeutic option for obesity management. This peptide, which targets three key receptors involved in metabolism, has shown significant promise in clinical trials, offering hope to those struggling with weight-related health issues.

Study Background

Obesity is a growing public health concern linked to numerous serious conditions such as diabetes and cardiovascular disease. Traditional treatments often fall short due to limited efficacy or adverse side effects. Retatrutide, a triple-receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), offers an innovative approach by modulating multiple pathways involved in appetite regulation and metabolism. Researchers aimed to assess its safety and efficacy through a systematic review of available clinical trial data.

What the Research Found

The study reviewed three clinical trials involving 691 participants, with an average age of 54 years (335 men and 356 women). Participants were randomly assigned to receive either retatrutide or placebo. The highest efficacy was observed in patients receiving a weekly subcutaneous injection of 12 mg retatrutide, who experienced significant reductions in body weight, BMI, and waist circumference compared to the placebo group. Specifically, more participants achieved weight losses of ≥5%, 10%, 15%, and 20% with retatrutide treatment.

What This Means for Peptide Users

For individuals struggling with obesity, these findings suggest that retatrutide could be a valuable addition to existing therapeutic options. The peptide's ability to target multiple metabolic pathways offers a more comprehensive approach to weight management compared to single-receptor agonists currently available on the market. However, it is important to note that gastrointestinal side effects were common among participants receiving retatrutide, which may influence patient compliance and long-term use.

Limitations and Caveats

While the results are promising, several limitations must be acknowledged. The systematic review included only three clinical trials, which limits the generalizability of findings. Additionally, adverse effects such as gastrointestinal discomfort were frequently reported among participants receiving retatrutide, indicating that further research is needed to address these issues.

How This Compares to Previous Research

Previous studies on single-receptor agonists like GLP-1R have shown efficacy in weight management but often come with limitations regarding long-term safety and effectiveness. Retatrutide's multi-target approach represents a significant advancement, potentially offering better outcomes for patients struggling with obesity. However, the limited number of clinical trials included in this review means that more research is necessary to confirm these findings.

Our Analysis

At PeptideVault, we view this systematic review as an important step forward in understanding the potential benefits and risks associated with retatrutide therapy. The peptide's mechanism of action targeting multiple metabolic pathways presents a promising avenue for obesity management. However, the need for larger-scale clinical trials to validate these findings and address safety concerns remains paramount.

Key Takeaways

  • Retatrutide shows significant promise in reducing body weight and improving metabolic health in obese patients.
  • The 12 mg dosage appears most effective based on current data.
  • Gastrointestinal side effects are common, which may impact patient adherence to treatment.
  • More extensive clinical trials are necessary to confirm these findings and address safety concerns.

Original Source

Citation: Misra Saurav, Narayan Ravi Kant, Kaur Manmeet (2025). Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. Journal of basic and clinical physiology and pharmacology. DOI: 10.1515/jbcpp-2025-0113

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

관련 연구

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.